Clostridium difficile infection and antibiotic-associated diarrhoea

Area of Science:

• Gastroenterology
• Microbiology
• Pharmacology

Background:

• Antibiotic-associated diarrhoea (AAD) is a frequent adverse effect of antibiotic therapy.
• Clostridium difficile infection (CDI) represents a severe form of AAD, leading to significant morbidity and mortality.
• Emerging research highlights the gut microbiota's role in AAD and CDI pathogenesis.

Purpose of the Study:

• To review the assessment and diagnostic approaches for AAD and CDI.
• To explore the therapeutic potential of modulating the gut microbiota for AAD and CDI treatment.
• To provide an overview of current and emerging treatment strategies for AAD and CDI.

Main Methods:

• Literature review of recent studies on AAD and CDI.
• Analysis of research on gut microbiota and its role in AAD/CDI.
• Synthesis of information on diagnostic and therapeutic interventions.

Main Results:

• AAD is common, with CDI posing a serious health risk.
• Gut microbiota dysbiosis is a key factor in CDI development.
• Microbiota-targeted therapies show promise for managing AAD and CDI.

Conclusions:

• Understanding gut microbiota dynamics is crucial for managing AAD and CDI.
• Novel therapeutic strategies focusing on microbiota restoration are under rapid development.
• Further research is needed to optimize microbiota-based interventions for AAD and CDI.